— Meet Abbey Mitchell, founder of My Healing Community: her lived experience with metastatic breast cancer, research-led patient advocacy, community work, and the purpose behind the free resources shared here.

— Evidence-based guide to apigenin in oncology, covering BCL-2 survival proteins, tumour signalling, senescence and SASP, immune effects, chemosensitisation, research by cancer-type, bioavailability, dosing, and safety.

— Evidence-based guide to aspirin in oncology, covering COX and platelet biology, tumour and immune mechanisms, cancer-specific evidence, PIK3CA-mutated colorectal cancer, dosing, bleeding risk, and interactions.

— Science-based hype-free guide to Atorvastatin in oncology, including mechanisms, evidence by cancer type summary, pharmacology context, and safety cautions

— Cross-cancer hub on autophagy as a treatment-escape pathway, including the three-part trilogy on early intervention, stack design, and host protection.

— Practical, evidence-aware support before and after biopsy—covering procedure choices, seeding and stress-response concerns, bleeding risks, sedation, supplement stop lists, recovery, urgent red flags, and clinician questions.

— This guide explains what common imaging tests are measuring, why results may not match exactly, and how to ask for focused comparison and follow-up

— Shared bone-metastasis hub covering actionable research summaries, standard bone-targeted therapies, integrative strategies, protocol notes, and community member experiences.

— Member-contributed bone-health hub covering DXA interpretation, lab work, diet, supplementation, exercise, and research notes.

— Evidence-based guide to berberine in oncology, including metabolism, microbial overlap, cancer-type evidence, and interaction cautions.

— Evidence-based guide to Boswellia (frankincense) in oncology—covering AKBA, cancer-type evidence, tumour biology, brain-tumour oedema, absorption, dosing, safety, interactions, and sourcing.

— Book recommendations for cancer patients, carers, and readers exploring integrative oncology, healing, metabolic approaches, repurposed drugs, and wider support.

— A hub for breast‑cancer resources, treatment‑resistance research summaries, metastatic support, and practical pathway tools for ER+, HER2‑positive and TNBC. Resources written by and for breast‑cancer patients, updated regularly. Contributors welcome.

— Practical comparison of palbociclib, ribociclib, and abemaciclib in HR-positive, HER2-negative advanced breast cancer—covering efficacy, dosing, side effects, QTc, neutropenia, supplements, interactions, and monitoring.

— Community support hub for people living with cancer, bringing together books, podcasts, online groups, discussion threads, trusted suppliers, discounts, and practical shared resources.

— Community discussion threads organised by cancer type for Healing Cancer Study Support Group members.

— Treatment directories, clinic-based offerings, and integrative practitioner directories for New Zealand, Europe, and the UK.

— Cimetidine's anti-metastatic and immune mechanisms.

— Community discussion threads for standard oncology drugs, side effects, and practical patient support questions.

— Explore curcumin in oncology: prevention and adjunctive-care evidence, inflammation and tumour-signalling pathways, evidence by cancer type, immune effects, enhanced formulations, dosing, safety, and drug interactions.

— Investigational metabolic adjunct in oncology, with pages on the overview, evidence by cancer type, the pancreatic study, lower-limit protocol debate, and practical sourcing.

— Anticancer evidence, clinical research patterns, safety and international access

— Repurposing rationale, mechanisms, evidence by cancer type, combinations, research dosing patterns, safety and international access

— Repurposing rationale, mechanisms, evidence by cancer type, combinations, research dosing patterns, safety and international access

— Cross-cancer guide to dormant cells and slow growing residual disease, treatment resistance and reactivation triggers, local-treatment questions, and team-discussion prompts.

— Plain-language guide to weighing laboratory and human supplement-interaction evidence, formulation differences, and practical safety questions.

— Evidence-based guide to EGCG, the main green-tea catechin studied in oncology—covering anticancer mechanisms, cancer-type evidence, immune effects, bioavailability, dosing, safety, interactions, and sourcing.

- Estrogen-receptor-positive/HER2-negative breast cancer research summaries that need their own treatment and resistance contexts.

- An overview of Emodin's pharmacological properties and its potential to modulate IL-4/IL-13 and IgG4 class switching, with cautions for use alongside cancer immunotherapy.

— A short guide for anyone noticing very hard, stiff, or "cement‑like" areas around tumours, outlining three layers — driver programme, fibrotic scaffold, and fibrin/perfusion — and where terrain‑level supports like melatonin, honokiol, flavonoids, nattokinase, lumbrokinase, bromelain and serrapeptase fit as adjuncts.

— Guide to the main integrative cancer care practitioner types, what each can help with, and directories for finding qualified support worldwide.

— Fungal-pathogen support content, including protocol-building material and related resources.

— Patient-facing guide to copper, heavy metal burden, pathogen overlap, testing choices, and practical next steps in oncology.

— HER2-positive breast-cancer topics that need their own treatment and resistance context

— Cancer immunotherapy, T-cell biology, gamma–delta T cells, macrophages, immune-cycle steps, biomarkers, R-Cu and cfChps and diet–gut-health research.

— Ivermectin in cancer: a simple checklist for a more informed look

— Plain-language breakdown of the 2026 cell study showing ESR1/ERα, HER2, and pSMAD2 suppression, with confirmed tamoxifen synergy.

— Evidence-based overview of itraconazole in oncology, including mechanisms, cancer-type evidence, dosing, safety, and sourcing.

— A 2026 research update on uterine and soft-tissue leiomyosarcoma covering cell signalling, metabolism, immune landscape, resistance mechanisms, clinical trials, and current standard care

— Practical liposomal-delivery hub covering empty liposomes, safety, liposomal melatonin, liposomal ivermectin, and nebulising cautions.

— Evidence-aware guide to Limosilactobacillus reuteri in oncology, including preclinical tumour biology, immunotherapy relevance, yoghurt preparation, capsule options, and safety cautions.

— Patient-facing guide to macrophages in cancer, including immune coordination, recovery time, and why washout windows can matter.

— Study-note hub covering melatonin's mitochondrial, immune, phase-separation, fibrotic, and dosing questions in oncology research.

— Evidence-based overview of mebendazole in oncology, including mechanisms, cancer-type evidence, dosing, safety, immune effects, and sourcing.

Evidence-based overview of silymarin and milk thistle in oncology, including liver support, cancer-type evidence, and interaction questions.

— Evidence includes laboratory studies, animal research, early human trials, randomised trials and case reports. These categories are kept separate.

— Evidence-based library of deep dives on natural compounds and selected molecules, including Apigenin, Berberine, Boswellia, Curcumin, EGCG, Polydatin, Shikonin, Urolithin A, Withaferin A, Milk thistle, and Usnea. An A–Z index of study support group discussion threads on natural compounds and molecules is also found here.

For many natural compounds, the gap between promising laboratory findings and well-designed human trials reflects more than scientific uncertainty.

— Structured deep dive on treatment-related nerve damage, red flags, standard care, and integrative supports. Study group members recommendations from over the years including treatments, devices, nutraceuticals and topical formulas. R-ALA, Zoltaran and Lodacaine unpacked in more detail.

— Direct deep dive on low neutrophils in cancer care, including chemotherapy-related, chronic, and post-treatment neutropenia.

— Repurposed-drug hubs, such as mebendazole and itraconazole, with safety, interaction, and discussion-thread context.

— Structured anti-pathogen protocol supports.

— Podcast recommendations for cancer patients, carers, and integrative oncology learners, including healing stories, survivorship, and practical support.

— Evidence-based overview of polydatin in oncology, including resveratrol-related mechanisms, cancer-type evidence, dosing, and safety.

- A hype-free deep-dive propranolol's proposed anticancer mechanisms, the evidence by cancer type, and the safety, dosing and access issues relevant to its off-label study in cancer care.

— Evidence-aware guide to ripe Pu‑erh tea, theabrownin, metabolic terrain support, sourcing, and practical brewing.

— 2026 Oncology research deep dive sitting within our community's Natural Medicines Research Support Hub.

Ganoderma lucidum) and STAT3 signalling in ER+ breast cancer

— Practical guide to resistant starch, food preparation, butyrate production, and why cooling cooked starches can change both glycaemic and gut effects.

— A detailed review of emerging research on the resveratrol–copper (R-Cu) protocol, including its reported effects on cell-free chromatin particles (cfChps), immune checkpoints and cancer-related biomarkers. It also clearly outlines the current evidence gaps and offers free community sourced information and resources.

— Cross-cancer hub on therapy-induced senescence, SASP biology, senolytic strategy, and treatment-survivor clean-up logic.

— This page is designed as a conservative, patient-facing framework for discussing intermittent natural senolytic-style pulses built around fisetin and quercetin, using currently available human dosing patterns as the foundation.

— Evidence-based overview of shikonin in oncology, including PKM2 inhibition, estrogen-receptor degradation, resistance sensitisation, and cancer-type evidence.

— Cross-cancer side-effect, symptom-support, and recovery topics, including overview pages and deeper symptom guides.

listening to the parts of us that are frightened by what we’re asking our bodies to endure.

- What common imaging tests are measuring, why results may not match exactly, and how to ask for focused comparison and follow

— Evidence-based overview of silymarin and milk thistle in oncology, including liver support, cancer-type evidence, and interaction questions.

— Vetted supplement suppliers and discount codes for our cancer research support community — MCS Formulas, Fullscript, Welldium & more

— Evidence-based perioperative guidance for cancer patients before and after surgery, including anaesthesia questions, supplement pauses, wound healing support, and post-op red flags.

— Testing ideas, biomarkers, bloodwork, and practical monitoring guidance.

— TP53 testing, mutation types, germline and somatic interpretation, and practical support questions.

— Community discussion threads on CT scans, DUTCH testing, genomic analysis and other diagnostic questions.

— Embodied support work, guided practices, and self-paced learning built around the twelve life energies.

— involves several interacting processes, and their importance can change over time. Understanding those relationships helps us ask more useful questions about what might matter now.

— Evidence-based overview of Urolithin A in oncology, including mitophagy, immune effects, cancer-type evidence, pharmacokinetics, and safety questions.

— Evidence-based overview of usnic acid from Usnea, including anticancer mechanisms, antifungal crossover, dosing context, and safety cautions.

— Evidence-based overview of withaferin A in oncology, including autophagy blockade, ER-α suppression, HSP90 disruption, pharmacokinetics, safety, and sourcing.